Jaguar Health, Inc. is moving forward with plans to enhance its employee compensation structure. The company has filed a definitive proxy statement seeking stockholder approval for an amendment to its 2014 Stock Incentive Plan. This amendment aims to increase the number of shares authorized for issuance under the plan, allowing for better employee incentives and retention.

The special meeting of stockholders is scheduled for November 6, 2026, where this proposal will be voted on. The company is requesting approval to increase the number of shares under the plan to 378,859, which would represent 14% of the issued and outstanding shares of common stock on a fully diluted basis as of September 30, 2026. This move is significant as it reflects Jaguar Health's commitment to attracting and retaining talent in a competitive market.

Background

Jaguar Health, Inc. operates in the pharmaceutical preparations sector, classified under the SIC code 2834. The company trades on the Nasdaq under the ticker symbol JAGX. Recently, it has filed several forms with the SEC, including a definitive proxy statement on October 8, 2026, and an 8-K on October 28, 2026, detailing its ongoing corporate actions.

What the Filing Says

The recent filing includes a supplement to the proxy statement, providing additional information regarding Proposal 3, which seeks to amend the stock incentive plan. The filing states, "The Company is providing the following supplement to disclose additional information regarding Proposal 3 in the Proxy Statement." This proposal is crucial as it not only aims to increase shares but also to ensure that the plan remains relevant in light of the recent Series R Preferred Stock Dividend.

Impact

This proposal may significantly affect current and potential employees of Jaguar Health, as it aims to enhance the compensation package available to them. Approval of the amendment would increase the number of shares available for issuance under the 2014 Plan, thereby expanding the potential for stock options and other equity-based compensation. This move could also influence other companies in the pharmaceutical preparations sector, prompting them to reassess their own employee incentive programs.

What's Next

The special meeting for stockholder voting is set for November 6, 2026. The outcome of this vote will determine whether the proposed amendment to the stock incentive plan will be approved, impacting the company's compensation strategy moving forward.